Cochrane · systematic review · CD013304
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
Mühlbauer, V, Möhler, R, Dichter, MN, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 7.1%Low 4 · 28.6%Moderate 7 · 50%High 2 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings ‐ Typical antipsychotics compared to placebo in people with Alzheimer's disease and vascular dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Agitation ‐ presented in units on CMAI (higher is worse)a ‐ 361 persons in 4 RCTs of 3 to 16 weeks Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision, inconsistency |
Response for agitation ‐ as defined by authors of RCTs ‐ 367 persons in 4 RCTs of 3 to 16 weeks Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)f ‐ 240 persons in 2 RCTs of 6 to 10 weeks Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Response for psychosis ‐ as defined by authors of RCTs ‐ 259 persons in 2 RCTs of 6 to 10 weeks Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Extrapyramidal symptoms ‐ Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | High |
Somnolence ‐ Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Death ‐ 578 persons in 6 RCTs of 3 to 16 weeks _________________________________________ Summary of findings ‐ Typical antipsychotics vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings ‐ Atypical antipsychotics compared to placebo in people with Alzheimer's disease and vascular dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Agitation ‐ presented in units on CMAI (higher is worse)a ‐ 1971 persons in 9 RCTs of 3 to 12 weeks Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision, inconsistency |
Extrapyramidal symptoms ‐ Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Somnolence ‐ Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | High |
Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________ Summary of findings ‐ Atypical antipsychotics vs placebo | no estimate extracted | NR | Moderate Downgraded: risk of bias, imprecision, inconsistency |